ClinicalTrials.gg
CompletedNCT00859898Updated Jul 7, 2016Results posted

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

A Phase 3 interventional study of Dapagliflozin and Metformin XR in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 123 sites in 6 countries. Open to participants aged 18 Years to 77 Years. Per ClinicalTrials.gov, last updated 2016-07-07.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,093
Allocation
Randomized
Ages
18 Years to 77 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
12th of 180
1,093 · median 82
Started
2009
with 10 others
Phase 3
47 of 180
4 open now
Registered
20th of 180
by date
Lead sponsor
72 of 180
AstraZeneca

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 12th largest by enrollment, is one of 11 that started in 2009, is one of 47 in phase 3, and was the 20th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 77 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The primary purpose of this study is to compare the change from baseline in hemoglobin A1C achieved with dapagliflozin 10 mg in combination with metformin XR as compared with metformin XR monotherapy and compared with Dapagliflozin monotherapy, after 24 weeks of oral administration of double-blind treatment. The safety of treatment with dapagliflozin will also be assessed in this study

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Diabetes Mellitus, Type 2
  • Diabetes Mellitus
  • Endocrine System Diseases
  • Glucose Metabolism Disorders
  • Metabolic Diseases
  • Metformin
  • Dapagliflozin
  • Hypoglycemic Agents
  • Pharmacologic Actions
  • Physiological Effects of Drugs
04

Who can participate

Ages eligible
18 Years to 77 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment naive males and females, >= 18 years old and

\<= 77 years old, with type 2 diabetes mellitus

  • Subjects must have central laboratory pre-randomization >= 7.5 and \<= 12.0%
  • C-peptide >= 1.0 ng/mL (0.34 nmol/L)
  • \<= 45 kg/m2
  • Must be able to perform self monitoring of blood glucose

Exclusion criteria

Exclusion Criteria:

  • (AST) and/or alanine aminotransferase (ALT) >3X* (ULN)
  • Serum Total >2 mg/dL (34.2 µmol/L)
  • Creatinine kinase >3*ULN
  • Serum creatinine >= 1.50 mg/dL (133 µmol/L) for male subjects, >= 1.40 mg/dL (124 µmol/L) for female subjects
  • Calcium value outside of the central laboratory normal reference range
  • Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases
  • Urine albumin:creatinine ratio (UACR) >1800 mg/g (203.4 mg/mmol Cr)
  • Severe uncontrolled hypertension defined as systolic blood pressure (SBP) >=180 mmHg and/or diastolic blood pressure (DBP) >=110 mmHg
  • >=11.0 g/dL (110 g/L) for men; hemoglobin >=10.0 g/dL (100 g/L) for women
  • Positive for surface antigen
  • Positive for anti- virus antibody
  • History of diabetes insipidus
  • History of diabetic ketoacidosis or hyperosmolar nonketotic coma
  • Symptoms of poorly controlled diabetes that would preclude participation in this trial
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,093 participants (actual)

Study arms

  • Experimental
    Dapagliflozin + Metformin XR

    Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks Metformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks

    Drug: Dapagliflozin · Drug: Metformin XR

  • Experimental
    Dapagliflozin + Placebo

    Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks. Placebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks.

    Drug: Dapagliflozin · Drug: metformin HCl Modified Release matching Placebo

  • Active comparator
    Metformin XR + Placebo

    Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks Placebo: Dapagliflozin matching placebo tablets once daily, 24 weeks

    Drug: Metformin XR · Drug: dapagliflozin matching Placebo

Interventions

  • Tablets, Oral, 10 mg, once daily, 24 weeks

    Also known as: Farxiga™

  • Tablets, Oral, up to 2000 mg, once daily, 24 weeks

    Also known as: Glucophage®

  • Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks

    Also known as: Glucophage®

  • Drugdapagliflozin matching Placebo

    Tablets

  • Drugmetformin HCl Modified Release matching Placebo

    Tablets

06

What researchers measure

Primary outcomes

  1. Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants

    Adjusted mean change in HbA1c from baseline at Week 24 (or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available, ie, last observation carried forward (LOCF) was determined. HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the Double-Blind Period.

    Time frame: Week 24

Secondary outcomes

  1. Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (LOCF) - Randomized, Treated Participants

    Data after rescue medication was excluded from this analysis. FPG was measured as milligrams per deciliter (mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the Double-Blind Period.

    Time frame: Week 24

  2. Percent Adjusted for Baseline HbA1c of Participants Achieving a Therapeutic Glycemic Response at Week 24 (LOCF) - Randomized, Treated Participants

    Therapeutic glycemic response was defined as HbA1c less than 7.0%. n=Number of participants with HBA1c less than (\<) 7 % at Week 24, last observation carried forward (LOCF) while N=number of randomized participants with non-missing baseline and Week 24 (LOCF) values. Percent=n/N and was adjusted for Baseline HbA1c. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.

    Time frame: Week 24

  3. Adjusted Mean Change From Baseline in HbA1C at Week 24 (LOCF) in Participants Whose Baseline HbA1C Category ≥9.0%

    HbA1c was measured as percent of hemoglobin by a central laboratory. The population included those randomized, treated participants whose Baseline HbA1c was greater than, equal to (\>=) 9.0%. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.

    Time frame: Week 24

  4. The Adjusted Mean Change From Baseline in Total Body Weight at Week 24 (LOCF) - Randomized, Treated Participants

    Adjusted mean change from baseline in total body weight at Week 24 (or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight was measured in kilograms (kg). Body weight measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the Double-Blind Period.

    Time frame: Week 24

  5. Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuation Due to AEs, During the 12 Week Double Blind Period, Including Data After Rescue - All Treated Participants

    Medical Dictionary for Regulatory Activities (MedDRA), version 12.1 AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug as per the investigator. Events captured from baseline to last dose plus 4 days for AEs, plus 30 days for SAEs during the Double Blind 12 Week Period. Data after rescue included.

    Time frame: Day 1 of Double Blind Period to end of Week 24 Plus 30 days

  6. Number of Participants With Adverse Events of Special Interest During the 12 Week Double Blind Period - All Treated Participants

    Participants with AEs of hypoglycemia, cardiac/vascular disorders, renal impairment or failure, volume depletion (hypotension/dehydration/hypovolemia), fractures, urinary stones, and other reports suggestive of genital infection or urinary tract infection (UTI) were summarized using MedDRA version 13.0. Data after rescue included for all special AEs except hypoglycemia (excluded data after rescue). Major hypoglycemic episode: symptomatic requiring 3rd party assistance due to severe impairment in consciousness or behavior with a glucose value \< 54 mg/dL and prompt recovery after glucose/glucagon; Minor: either symptomatic with glucose measurement \< 63 mg/dL, regardless of need for 3rd party assistance, or asymptomatic with glucose \< 63 mg/dL that does not qualify as major; Other: suggestive but not meeting criteria for major or minor.

    Time frame: Baseline to last dose plus 4 days in 12 Week Double Blind Period

  7. Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure at Week 24 - Treated Participants

    Measurements were taken during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 in the Double Blind Period. Blood pressure values were obtained: after the participant was seated quietly for 5 minutes; at least 8 hours after the last ingestion of caffeine, alcohol, or nicotine; and in the same arm (right or left) consistently through out the study. Systolic and Diastolic pressures were measured in millimeters of mercury (mmHg). Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.

    Time frame: Week 24

  8. Mean Change From Baseline in Seated Heart Rate at Week 24 - Randomized, Treated Participants

    Measurements were taken during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 in the Double Blind Period. Heart rate values were obtained: after the participant was seated quietly for 5 minutes; at least 8 hours after the last ingestion of caffeine, alcohol, or nicotine; and in the same arm (right or left) consistently throughout the study. Heart rate was measured in beats per minute (bpm). Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.

    Time frame: Week 24

  9. Number of Participants With Normal or Abnormal Electrocardiogram Summary Tracing at Week 24 (LOCF) - Randomized, Treated Participants

    12-Lead electrocardiograms (ECGs) were performed at entry into Lead-In Period Day -7 visit and Week 24/End of treatment visit (last observation carried forward) on participants who were supine. ECGs were assessed by the investigator. Baseline (BL) was Day -7 for this parameter. Data after rescue included.

    Time frame: Week 24

  10. Number of Participants With Marked Laboratory Abnormalities (Not Including Liver Function) in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants

    Laboratory samples: Qualification and Lead-In Periods, Day 1, Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of Double-Blind Period. Baseline (BL)=last assessment prior to start of first dose of double-blind study medication. Data after rescue included. Pretreatment (PreRX); grams per deciliter (g/dL); upper limit of normal (ULN); milliequivalent per liter (mEq/L); Units per liter (U/L), blood urea nitrogen (BUN). Marked abnormality Low (High) defined: hemoglobin \<6 (\>18 females or \>20 males) g/dL; hematocrit \<20% ( \>55% females or \>60% males); creatinine (\>=1.5\*preRX, \>=2.5 mg/dL); glucose \<54 (\>350) mg/dL; creatine kinase (\>5\*ULN);calcium \<7.5 (\>=1 mg/dL from ULN and \>= 0.5mg/dL from PreRX); sodium \<130 or \< 120 male/female (\>150 mEq/L; potassium \<=2.5 (\>=6.0) mEq/L; bicarbonate \<= 13 mEq/L; inorganic phosphorus: \<=1.8 if age 17-65 or \<=2.1 if age \>=66, (\>=5.6 if age 17-65 or \>=5.1) mg/dL if age \>=66; albumin \<=2 (\>6) g/dL; urine albumin(alb) / creatinine (creat) ratio (\>1800 mg/g)

    Time frame: Baseline to Week 24/end of treatment plus 4 days

  11. Number of Participants With Marked Laboratory Abnormalities in Liver Function in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants

    Safety laboratory measurements were obtained during the Qualification and Lead-In Periods and on Day 1 of the Double-Blind Period and at Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24. BL was defined as the last assessment prior to the start of the first dose of the double-blind study medication. Data included from BL up to and including the last day of treatment plus 30 days. Liver function abnormality criteria: FDA Guidance for Industry: Premarketing Clinical Evaluation (July 2009). Data after rescue was also included. Abbreviations: Pretreatment (PreRX), upper limit of normal (ULN); greater than (\>) less than (\<); Units per liter (U/L), alanine aminotransferase (ALT); aspartate aminotransferase (AST); alkaline phosphatase (ALP). Marked abnormality Low (High) defined: ALP, AST and ALT (\>3\*ULN); bilirubin (\>2\*ULN if PreRX \<= ULN; \>3\*ULN if PreRX \> ULN); AST or ALT plus (+) bilirubin elevation: AST or ALT \>3\*ULN and bilirubin \>1.5\*ULN within 14 days on or after ALT elevation.

    Time frame: Baseline to Week 24/end of treatment plus 30 days

07

Results

Posted Mar 20, 2014

Participant flow

Participants were recruited from 13-April-2009 to 26-November-2009. Study completed 12-May-2010. Drug naive participants with Type 2 Diabetes Mellitus who had inadequate glycemic control with diet and exercise. Inadequate glycemic control was defined as a hemoglobin A1c (HbA1c) ≥ 7.5% and ≤ 12.0%.

Participant flow — Overall Study
MilestoneDapagliflozin + Metformin XRDapagliflozinMetformin XR
Started211219208
Completed183188181
Not completed283127
Withdrew: Lack of efficacy011
Withdrew: Adverse event498
Withdrew: Withdrawal by subject11811
Withdrew: Death001
Withdrew: Lost to follow-up10115
Withdrew: Poor/non-compliance200
Withdrew: No longer meets criteria010
Withdrew: Non-specified111

Outcome measures

PrimaryAdjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants

Adjusted mean change in HbA1c from baseline at Week 24 (or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available, ie, last observation carried forward (LOCF) was determined. HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the Double-Blind Period.

Time frame:
Week 24
Reported as:
Mean · Percent of hemoglobin
Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants
Percent of hemoglobinDapagliflozin + Metformin XRDapagliflozinMetformin XR
Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants-1.98 ± 0.0759-1.45 ± 0.0734-1.44 ± 0.0757
Statistical analysis
  • Dapagliflozin + Metformin XR vs Dapagliflozin · ANCOVA · p = <0.0001 (Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant. Two-sided significance level at α=0.05) · Mean difference (final values): -0.53 · 95% CI -0.74 to -0.32treatment group as an effect and the baseline HbA1c value as a covariate.
  • Dapagliflozin + Metformin XR vs Metformin XR · ANCOVA · p = <0.0001 (Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant. Two-sided significance level at α=0.05) · Mean difference (final values): -0.54 · 95% CI -0.75 to -0.33treatment group as an effect and the baseline HbA1c value as a covariate.
  • Dapagliflozin vs Metformin XR · ANCOVA · Mean difference (final values): -0.01 · 95% CI -0.22 to 0.20treatment group as an effect and the baseline value as a covariate
  • Dapagliflozin vs Metformin XR · ANCOVA · p = 0.9144 (two-sided significance level at α=0.05) · Mean difference (final values): -0.01 · 95% CI -0.22 to 0.20treatment group as an effect and the baseline HbA1c value as a covariate.
SecondaryAdjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (LOCF) - Randomized, Treated Participants

Data after rescue medication was excluded from this analysis. FPG was measured as milligrams per deciliter (mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the Double-Blind Period.

Time frame:
Week 24
Reported as:
Mean · mg/dL
Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (LOCF) - Randomized, Treated Participants
mg/dLDapagliflozin + Metformin XRDapagliflozinMetformin XR
Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (LOCF) - Randomized, Treated Participants-60.4 ± 2.533-46.4 ± 2.494-34.8 ± 2.545
Statistical analysis
  • Dapagliflozin + Metformin XR vs Dapagliflozin · ANCOVA · p = <0.0001 (two-sided significance level at α=0.05. Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant.) · Mean difference (final values): -13.9 · 95% CI -20.9 to -7.0treatment group as an effect and the baseline value as a covariate.
  • Dapagliflozin + Metformin XR vs Metformin XR · ANCOVA · p = <0.0001 (two-sided significance level at α=0.05. Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant.) · Mean difference (final values): -25.5 · 95% CI -32.6 to -18.5treatment group as an effect and the baseline value as a covariate.
  • Dapagliflozin vs Metformin XR · ANCOVA · Mean difference (final values): -11.6 · 95% CI -18.6 to -4.6treatment group as an effect and the baseline value as a covariate
  • Dapagliflozin vs Metformin XR · ANCOVA · p = 0.0012 (two-sided significance level at α=0.05.) · Mean difference (final values): -11.6 · 95% CI -18.6 to -4.6treatment group as an effect and the baseline value as a covariate.
SecondaryPercent Adjusted for Baseline HbA1c of Participants Achieving a Therapeutic Glycemic Response at Week 24 (LOCF) - Randomized, Treated Participants

Therapeutic glycemic response was defined as HbA1c less than 7.0%. n=Number of participants with HBA1c less than (\<) 7 % at Week 24, last observation carried forward (LOCF) while N=number of randomized participants with non-missing baseline and Week 24 (LOCF) values. Percent=n/N and was adjusted for Baseline HbA1c. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.

Time frame:
Week 24
Reported as:
Number · Percent of participants
Percent Adjusted for Baseline HbA1c of Participants Achieving a Therapeutic Glycemic Response at Week 24 (LOCF) - Randomized, Treated Participants
Percent of participantsDapagliflozin + Metformin XRDapagliflozinMetformin XR
Percent Adjusted for Baseline HbA1c of Participants Achieving a Therapeutic Glycemic Response at Week 24 (LOCF) - Randomized, Treated Participants46.6 (40.1 to 53.0)31.7 (25.7 to 37.7)35.5 (28.8 to 41.7)
Statistical analysis
  • Dapagliflozin + Metformin XR vs Dapagliflozin · Regression, Logistic · p = 0.0012 (Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant.) · Mean difference (final values): 14.9 · 95% CI 5.9 to 23.9Logistic regression based on the methodology of Zhang, Tsiatis and Davidian and Tsiatis, Davidian, Zhang and Lu, with adjustment for baseline HbA1c.
  • Dapagliflozin + Metformin XR vs Metformin XR · Regression, Logistic · p = 0.0165 (Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant.) · Mean difference (final values): 11.3 · 95% CI 2.1 to 20.6Logistic regression based on the methodology of Zhang, Tsiatis and Davidian and Tsiatis, Davidian, Zhang and Lu, with adjustment for baseline HbA1c.
SecondaryAdjusted Mean Change From Baseline in HbA1C at Week 24 (LOCF) in Participants Whose Baseline HbA1C Category ≥9.0%

HbA1c was measured as percent of hemoglobin by a central laboratory. The population included those randomized, treated participants whose Baseline HbA1c was greater than, equal to (\>=) 9.0%. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.

Time frame:
Week 24
Reported as:
Mean · Percent of Hemoglobin
Adjusted Mean Change From Baseline in HbA1C at Week 24 (LOCF) in Participants Whose Baseline HbA1C Category ≥9.0%
Percent of HemoglobinDapagliflozin + Metformin XRDapagliflozinMetformin XR
Adjusted Mean Change From Baseline in HbA1C at Week 24 (LOCF) in Participants Whose Baseline HbA1C Category ≥9.0%-2.59 ± 0.1249-2.14 ± 0.1305-2.05 ± 0.1318
Statistical analysis
  • Dapagliflozin + Metformin XR vs Dapagliflozin · ANCOVA · p = 0.0133 (two-sided significance level at α=0.05. Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant.) · Mean difference (final values): -0.45 · 95% CI -0.81 to -0.09: treatment group as an effect and the baseline HbA1c value as a covariate.
  • Dapagliflozin + Metformin XR vs Metformin XR · ANCOVA · p = 0.0036 (two-sided significance level at α=0.05. Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant.) · Mean difference (final values): -0.53 · 95% CI -0.89 to -0.18treatment group as an effect and the baseline HbA1c value as a covariate.
SecondaryThe Adjusted Mean Change From Baseline in Total Body Weight at Week 24 (LOCF) - Randomized, Treated Participants

Adjusted mean change from baseline in total body weight at Week 24 (or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight was measured in kilograms (kg). Body weight measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the Double-Blind Period.

Time frame:
Week 24
Reported as:
Mean · kg
The Adjusted Mean Change From Baseline in Total Body Weight at Week 24 (LOCF) - Randomized, Treated Participants
kgDapagliflozin + Metformin XRDapagliflozinMetformin XR
The Adjusted Mean Change From Baseline in Total Body Weight at Week 24 (LOCF) - Randomized, Treated Participants-3.33 ± 0.2401-2.73 ± 0.2346-1.36 ± 0.2408
Statistical analysis
  • Dapagliflozin + Metformin XR vs Metformin XR · ANCOVA · p = <0.0001 (two-sided significance level at α=0.05) · Mean difference (final values): -1.97 · 95% CI -2.64 to -1.30treatment group as an effect and the baseline value as a covariate.
  • Dapagliflozin vs Metformin XR · ANCOVA · p = <0.0001 (two-sided significance level at α=0.05) · Mean difference (final values): -1.37 · 95% CI -2.03 to -0.71treatment group as an effect and the baseline value as a covariate
SecondaryNumber of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuation Due to AEs, During the 12 Week Double Blind Period, Including Data After Rescue - All Treated Participants

Medical Dictionary for Regulatory Activities (MedDRA), version 12.1 AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug as per the investigator. Events captured from baseline to last dose plus 4 days for AEs, plus 30 days for SAEs during the Double Blind 12 Week Period. Data after rescue included.

Time frame:
Day 1 of Double Blind Period to end of Week 24 Plus 30 days
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuation Due to AEs, During the 12 Week Double Blind Period, Including Data After Rescue - All Treated Participants
participantsDapagliflozin + Metformin XRDapagliflozinMetformin XR
Adverse Event (AE)126132118
Related Adverse Event344732
Serious Adverse Event (SAE)354
Related SAE011
Discontinued due to AE498
Deaths001
Discontinued due to SAE011
SecondaryNumber of Participants With Adverse Events of Special Interest During the 12 Week Double Blind Period - All Treated Participants

Participants with AEs of hypoglycemia, cardiac/vascular disorders, renal impairment or failure, volume depletion (hypotension/dehydration/hypovolemia), fractures, urinary stones, and other reports suggestive of genital infection or urinary tract infection (UTI) were summarized using MedDRA version 13.0. Data after rescue included for all special AEs except hypoglycemia (excluded data after rescue). Major hypoglycemic episode: symptomatic requiring 3rd party assistance due to severe impairment in consciousness or behavior with a glucose value \< 54 mg/dL and prompt recovery after glucose/glucagon; Minor: either symptomatic with glucose measurement \< 63 mg/dL, regardless of need for 3rd party assistance, or asymptomatic with glucose \< 63 mg/dL that does not qualify as major; Other: suggestive but not meeting criteria for major or minor.

Time frame:
Baseline to last dose plus 4 days in 12 Week Double Blind Period
Reported as:
Number · participants
Number of Participants With Adverse Events of Special Interest During the 12 Week Double Blind Period - All Treated Participants
participantsDapagliflozin + Metformin XRDapagliflozinMetformin XR
Cardiac Disorder AEs335
Vascular Disorder AEs4108
Hypoglycemia AEs (excluding data after rescue)726
Hypoglycemia Major Episode000
Hypoglycemia Minor Episode101
Hypoglycemia Other Episode625
AEs Suggestive of Genital Infection18285
AEs Suggestive of UTI16249
AEs of Renal Impairment or Failure241
AEs of Hypotension010
AEs of Syncope010
AEs of Fracture210
AEs of Urinary Stones001
SecondaryMean Change From Baseline in Seated Systolic and Diastolic Blood Pressure at Week 24 - Treated Participants

Measurements were taken during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 in the Double Blind Period. Blood pressure values were obtained: after the participant was seated quietly for 5 minutes; at least 8 hours after the last ingestion of caffeine, alcohol, or nicotine; and in the same arm (right or left) consistently through out the study. Systolic and Diastolic pressures were measured in millimeters of mercury (mmHg). Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.

Time frame:
Week 24
Reported as:
Mean · mmHg
Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure at Week 24 - Treated Participants
mmHgDapagliflozin + Metformin XRDapagliflozinMetformin XR
Systolic (N=182, 185, 179)-3.3 ± 0.947-4.0 ± 0.883-1.2 ± 1.010
Diastolic (N=182, 185, 179)-1.8 ± 0.579-1.9 ± 0.5250.0 ± 0.606
SecondaryMean Change From Baseline in Seated Heart Rate at Week 24 - Randomized, Treated Participants

Measurements were taken during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 in the Double Blind Period. Heart rate values were obtained: after the participant was seated quietly for 5 minutes; at least 8 hours after the last ingestion of caffeine, alcohol, or nicotine; and in the same arm (right or left) consistently throughout the study. Heart rate was measured in beats per minute (bpm). Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.

Time frame:
Week 24
Reported as:
Mean · bpm
Mean Change From Baseline in Seated Heart Rate at Week 24 - Randomized, Treated Participants
bpmDapagliflozin + Metformin XRDapagliflozinMetformin XR
Mean Change From Baseline in Seated Heart Rate at Week 24 - Randomized, Treated Participants0.6 ± 0.607-0.1 ± 0.5930.5 ± 0.594
SecondaryNumber of Participants With Normal or Abnormal Electrocardiogram Summary Tracing at Week 24 (LOCF) - Randomized, Treated Participants

12-Lead electrocardiograms (ECGs) were performed at entry into Lead-In Period Day -7 visit and Week 24/End of treatment visit (last observation carried forward) on participants who were supine. ECGs were assessed by the investigator. Baseline (BL) was Day -7 for this parameter. Data after rescue included.

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants With Normal or Abnormal Electrocardiogram Summary Tracing at Week 24 (LOCF) - Randomized, Treated Participants
participantsDapagliflozin + Metformin XRDapagliflozinMetformin XR
Normal at BL, Normal at Week 24 (N=211, 219, 208)10110794
Abnormal BL, Normal at Week 24 (N=211, 219, 208)151322
Normal BL, Abnormal at Week 24 (N=211, 219, 208)1889
Abnormal BL, Abnormal at Week 24 (N=211, 219, 208)536859
Normal at BL, Not Reported at Week 24191515
Abnormal at BL, Not Reported at Week 24588
Not Reported at BL, Abnormal at Week 24001
SecondaryNumber of Participants With Marked Laboratory Abnormalities (Not Including Liver Function) in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants

Laboratory samples: Qualification and Lead-In Periods, Day 1, Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of Double-Blind Period. Baseline (BL)=last assessment prior to start of first dose of double-blind study medication. Data after rescue included. Pretreatment (PreRX); grams per deciliter (g/dL); upper limit of normal (ULN); milliequivalent per liter (mEq/L); Units per liter (U/L), blood urea nitrogen (BUN). Marked abnormality Low (High) defined: hemoglobin \<6 (\>18 females or \>20 males) g/dL; hematocrit \<20% ( \>55% females or \>60% males); creatinine (\>=1.5\*preRX, \>=2.5 mg/dL); glucose \<54 (\>350) mg/dL; creatine kinase (\>5\*ULN);calcium \<7.5 (\>=1 mg/dL from ULN and \>= 0.5mg/dL from PreRX); sodium \<130 or \< 120 male/female (\>150 mEq/L; potassium \<=2.5 (\>=6.0) mEq/L; bicarbonate \<= 13 mEq/L; inorganic phosphorus: \<=1.8 if age 17-65 or \<=2.1 if age \>=66, (\>=5.6 if age 17-65 or \>=5.1) mg/dL if age \>=66; albumin \<=2 (\>6) g/dL; urine albumin(alb) / creatinine (creat) ratio (\>1800 mg/g)

Time frame:
Baseline to Week 24/end of treatment plus 4 days
Reported as:
Number · participants
Number of Participants With Marked Laboratory Abnormalities (Not Including Liver Function) in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants
participantsDapagliflozin + Metformin XRDapagliflozinMetformin XR
Hematocrit High > 55% (N=209, 218, 206)141
Hemoglobin High >18 g/dL(N=209, 218, 207)541
Creatinine >1.5*PreRX (N=209, 218, 207)825
Glucose High > 350 mg/dL (N=209, 218, 207)123
Albumin low or high (N=209, 218, 207)000
Calcium Low <7.5mg/dL (N=209, 218, 207)121
Calcium High >=1mg/dL+ULN (N=209, 218, 207)020
Bicarbonate Low <=13mEq/L (N=209, 218, 207)300
Potassium High >=6 mEq/L (N=209, 218, 207)236
Sodium Low <130 mEq/L (N=209, 218, 207)222
Sodium High >150 mEq/L (N=209, 218, 207)552
Sodium Low <120 mEq/L (N=209, 218, 207)010
inorganic phosphorus (high)(N=209, 218, 207)7133
Urine albumin/creat ratio (high)(N=209, 218, 206)031
SecondaryNumber of Participants With Marked Laboratory Abnormalities in Liver Function in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants

Safety laboratory measurements were obtained during the Qualification and Lead-In Periods and on Day 1 of the Double-Blind Period and at Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24. BL was defined as the last assessment prior to the start of the first dose of the double-blind study medication. Data included from BL up to and including the last day of treatment plus 30 days. Liver function abnormality criteria: FDA Guidance for Industry: Premarketing Clinical Evaluation (July 2009). Data after rescue was also included. Abbreviations: Pretreatment (PreRX), upper limit of normal (ULN); greater than (\>) less than (\<); Units per liter (U/L), alanine aminotransferase (ALT); aspartate aminotransferase (AST); alkaline phosphatase (ALP). Marked abnormality Low (High) defined: ALP, AST and ALT (\>3\*ULN); bilirubin (\>2\*ULN if PreRX \<= ULN; \>3\*ULN if PreRX \> ULN); AST or ALT plus (+) bilirubin elevation: AST or ALT \>3\*ULN and bilirubin \>1.5\*ULN within 14 days on or after ALT elevation.

Time frame:
Baseline to Week 24/end of treatment plus 30 days
Reported as:
Number · participants
Number of Participants With Marked Laboratory Abnormalities in Liver Function in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants
participantsDapagliflozin + Metformin XRDapagliflozinMetformin XR
AST >3*ULN (N=210, 219, 208)232
AST >5*ULN (N=210, 219, 208)011
ALT >3*ULN (N=210, 219, 208)247
ALT >5*ULN (N=210, 219, 208)012
ALT >10*ULN (N=210, 219, 208)001
AST or ALT > 3*ULN (N=210, 219, 208)357
AST or ALT > 5*ULN (N=210, 219, 208)012
AST or ALT > 10*ULN (N=210, 219, 208)001
Total bilirubin >1.5*ULN (N=210, 219, 207)021
AST or ALT + Bilirubin (High) (N=210, 219, 208)001
ALP >1.5*ULN (N=210, 219, 208)543
ALP >3*ULN (N=210, 219, 208)001

Adverse events

Collected over 24 Weeks plus 30 days; Day 1 of double blind treatment to last patient, last visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapagliflozin—5/219 (2.3%)32/219 (14.6%)
Dapagliflozin + Metformin XR—3/211 (1.4%)26/211 (12.3%)
Metformin XR—4/208 (1.9%)24/208 (11.5%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventDapagliflozinDapagliflozin + Metformin XRMetformin XR
OverdoseInjury, poisoning and procedural complications1/2190/2112/208
Myocardial infarctionCardiac disorders0/2191/2111/208
Back painMusculoskeletal and connective tissue disorders0/2190/2111/208
PainGeneral disorders0/2190/2111/208
Angina unstableCardiac disorders0/2191/2110/208
Facial bones fractureInjury, poisoning and procedural complications0/2191/2110/208
Lung abscessInfections and infestations1/2190/2110/208
OsteoarthritisMusculoskeletal and connective tissue disorders1/2190/2110/208
RectoceleReproductive system and breast disorders1/2190/2110/208
PneumoniaInfections and infestations1/2190/2110/208
Most frequent other events
Most frequent other events
EventDapagliflozinDapagliflozin + Metformin XRMetformin XR
DiarrhoeaGastrointestinal disorders6/21915/21120/208
Urinary tract infectionInfections and infestations17/2196/2114/208
Vulvovaginal mycotic infectionInfections and infestations11/2197/2111/208

Baseline characteristics

All randomized participants who took at least one dose of double-blind study medication.

Age, Continuous
Age, Continuous(years)Dapagliflozin + Metformin XRDapagliflozinMetformin XRTotal
Mean51.0 ± 10.1351.1 ± 11.5352.7 ± 10.3851.6 ± 10.72
Age, Customized
Age, Customized(participants)Dapagliflozin + Metformin XRDapagliflozinMetformin XRTotal
Less than (<) 65 years190192181563
Greater than, equal to (>=) 65 and < 75 years21242570
>= 75 years0325
Not Reported0000
Age, Customized
Age, Customized(participants)Dapagliflozin + Metformin XRDapagliflozinMetformin XRTotal
Female <= 50 years434444131
Female > 50 years627067199
Sex: Female, Male
Sex: Female, Male(Participants)Dapagliflozin + Metformin XRDapagliflozinMetformin XRTotal
Female105114111330
Male10610597308
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dapagliflozin + Metformin XRDapagliflozinMetformin XRTotal
Hispanic or Latino343435103
Not Hispanic or Latino546354171
Unknown or Not Reported123122119364
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Dapagliflozin + Metformin XRDapagliflozinMetformin XRTotal
White174176166516
Black/African American1113832
Asian24273182
Other Race2338
Body Mass Index
Body Mass Index(participants)Dapagliflozin + Metformin XRDapagliflozinMetformin XRTotal
< 25 kg/m^220252166
>= 25 kg/m^2 - <27 kg/m^223242067
>= 27 kg/m^2 - <30 kg/m^2453949133
>= 30 kg/m^2123131118372
Waist Circumference
Waist Circumference(cm)Dapagliflozin + Metformin XRDapagliflozinMetformin XRTotal
Mean104.33 ± 13.678103.86 ± 12.805103.03 ± 13.224103.75 ± 13.225

2 further baseline measures are reported on the registry.

08

Study locations

123 sites
  • International Institute Of Clinical Research
    Ozark, Alabama 36360, United States
  • Clinical Research Advantage, Inc./Mesa Family Med Ctr, Pc
    Tempe, Arizona 85282, United States
  • Clinical Research Advantage, Inc.
    Tempe, Arizona 85282, United States
  • John Muir Physician Network Clinical Research Center
    Concord, California 94520, United States
  • Encompass Clinical Research-North Coast
    Encinitas, California 92024, United States
  • Southland Clinical Research Center, Inc.
    Fountain Valley, California 92708, United States
  • Valley Research
    Fresno, California 93720, United States
  • Del Rosario Medical Clinic, Inc.
    Huntington Park, California 90255, United States
  • Irvine Center For Clinical Research, Inc.
    Irvine, California 92618, United States
  • Pacific Sleep Medicine Services (Avastra Clinical Trials)
    Redlands, California 92373, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Lynn Institute Of The Rockies
    Colorado Springs, Colorado 80907, United States
  • Radiant Research, Inc.
    Denver, Colorado 80239, United States
  • Clinical Therapeutics Corporation
    Coral Gables, Florida 33134, United States
  • Nextphase Clinical Trials, Inc.
    Miami, Florida 33145, United States
  • Baptist Diabetes Associates
    Miami, Florida 33156, United States
  • Metabolic Research Institute, Inc.
    W Palm Beach, Florida 33401, United States
  • Lake Hartwell Family Medicine
    Hartwell, Georgia 30643, United States
  • Middle Georgia Drug Study Center, Llc
    Perry, Georgia 31069, United States
  • Northwest Clinical Trials
    Boise, Idaho 83704, United States
  • Provident Clinical Research
    Addison, Illinois 60101, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Deerbrook Medical Associates
    Vernon Hills, Illinois 60061, United States
  • Physicians Research Group
    Indianapolis, Indiana 46250, United States
  • Borgess Research Institute
    Kalamazoo, Michigan 49048, United States
  • Olive Branch Family Medical Center
    Olive Branch, Mississippi 38654, United States
  • Clinilabs, Inc.
    New York, New York 10019, United States
  • Metrolina Medical Research
    Charlotte, North Carolina 28209, United States
  • Pharmquest
    Greensboro, North Carolina 27408, United States
  • Crescent Medical Research
    Salisbury, North Carolina 28144, United States
  • Community Health Care, Inc.
    Canal Fulton, Ohio 44614, United States
  • Holzer Clinic, Inc
    Gallipolis, Ohio 45631, United States
  • Wells Institute For Health Awareness
    Kettering, Ohio 45429, United States
  • Newark Physician Associates
    Newark, Ohio 43055, United States
  • Daniel G. Williams, Md
    Perrysburg, Ohio 43551, United States
  • Physician Research, Inc.
    Zanesville, Ohio 43701, United States
  • Gilbert Medical Research, Llc
    Bethany, Oklahoma 73008, United States
  • Tulsa Clinical Research, Llc
    Tulsa, Oklahoma 74104, United States
  • Integris Family Care Yukon
    Yukon, Oklahoma 73099, United States
  • Williamette Valley Clinical Studies
    Eugene, Oregon 97404, United States
  • Dingmans Medical
    Dingmans Ferry, Pennsylvania 18328, United States
  • Integrated Medical Group Pc/Fleetwood Clinical Research
    Fleetwood, Pennsylvania 19522, United States
  • Wellmon Family Practice
    Shippensburg, Pennsylvania 17257, United States
  • Safe Harbor Clinical Research
    E. Providence, Rhode Island 02914, United States
  • Southeastern Research Associates, Inc.
    Greenville, South Carolina 29605, United States
  • Holston Medical Group
    Bristol, Tennessee 37620, United States
  • Parkway Medical Group
    Fayetteville, Tennessee 37334, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Southwind Medical Specialists
    Memphis, Tennessee 38125, United States
  • Dallas Diabetes & Endocrine Center
    Dallas, Texas 75230, United States
  • Endocrine Associates
    Houston, Texas 77004, United States
  • Village Family Practice
    Houston, Texas 77024, United States
  • Juno Research, Llc.
    Houston, Texas 77036, United States
  • Non-Invasive Cardiovascular, Pa
    Houston, Texas 77074, United States
  • Excel Clinical Research
    Houston, Texas 77081, United States
  • Texas Center For Drug Development
    Houston, Texas 77081, United States
  • Midland Clinical Research Center
    Midland, Texas 79707, United States
  • Hill Country Medical Associates
    New Braunfels, Texas 78130, United States
  • Covenant Clinical Research, Pa
    San Antonio, Texas 78229, United States
  • S.A.M. Clinical Research Center
    San Antonio, Texas 78229, United States
  • Avastra Clinical Trials
    Midvale, Utah 84047, United States
  • Seven Corners Medical Center
    Falls Church, Virginia 22044, United States
  • Tidewater Integrated Medical Research
    Virginia Beach, Virginia 23454, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Local Institution
    Hyderabad, Andhra Pradesh 500034, India
  • Local Institution
    Aminjikarai, Chennai 600029, India
  • Local Institution
    Haryana, Karnal 132001, India
  • Local Institution
    Bangalore, Karnataka 560054, India
  • Local Institution
    Indore, Madhya Pradesh 452010, India
  • Local Institution
    Nagpur, Maharashtra 440010, India
  • Local Institution
    Nagpur, Maharashtra 440012, India
  • Local Institution
    Chennai, Tamilnadu 600020, India
  • Local Institution
    Ghaziabad, Uttar Pradesh 201002, India
  • Local Institution
    Jaipur, 302001, India
  • Local Institution
    Bucheon, Gyeonggi-Do 420-717, Korea, Republic of
  • Local Institution
    Goyang-Si, Gyeonggi-Do 410773, Korea, Republic of
  • Local Institution
    Guri-Si, Gyeonggi-Do 471-701, Korea, Republic of
  • Local Institution
    Sungnam, Gyeonggi-Do 463-070, Korea, Republic of
  • Local Institution
    Daegu, 700-721, Korea, Republic of
  • Local Institution
    Incheon, 405-760, Korea, Republic of
  • Local Institution
    Seoul, 137040, Korea, Republic of
  • Local Institution
    Guadalajara, Jalisco 44100, Mexico
  • Local Institution
    Guadalajara, Jalisco CP 44650, Mexico
  • Local Institution
    Guadalajara, Jalisco CP 44670, Mexico
  • Local Institution
    Morelia, Michioacan 58070, Mexico
  • Local Institution
    Cuernavaca, Morelos 62448, Mexico
  • Local Institution
    Monterrey, Nuevo Leon 64000, Mexico
  • Local Institution
    Monterrey, Nuevo Leon 64460, Mexico
  • Local Institution
    Merida, Yucatan 97070, Mexico
  • Local Institution
    Aguascalientes, 20230, Mexico
  • Local Institution
    Durango, 34000, Mexico
  • Local Institution
    Veracruz, CP 91910, Mexico
  • Local Institution
    Fajardo, 00738, Puerto Rico
  • Local Institution
    Ponce, 00716, Puerto Rico
  • Local Institution
    Ponce, 00717, Puerto Rico
  • Local Institution
    San Juan, 00909, Puerto Rico
  • Local Institution
    San Juan, 00920, Puerto Rico
  • Local Institution
    San Juan, 00926, Puerto Rico
  • Local Institution
    Ekaterinaburg, 620043, Russian Federation
  • Local Institution
    Kemerovo, 650029, Russian Federation

Showing the first 100 of 123 sites across 6 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol. 2016 Jun;29(3):391-400. doi: 10.1007/s40620-016-0261-1. Epub 2016 Feb 19. PubMed 26894924 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2009
First posted
Mar 11, 2009
Start
Apr 2009
Primary completionActual
May 2010
CompletionActual
May 2010
Results first posted
Mar 20, 2014
Last update
Jul 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00859898
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 11, 2009
Start date
Apr 2009
Primary completion
May 2010
Completion
May 2010
Results posted
Mar 20, 2014
Last update
Jul 7, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dapagliflozin · Metformin

Start the discussion